Tag archive for ‘EAMS’
Northwest Biotherapeutics: Exciting News on Potential for Early Patient Access for DCVax-L in the UK
UK designates DCVax-L as first drug to be considered for early access approval under recently enacted EAMS program. Earlier this year, Germany granted approval to DCVax-L under its early access program. Early access means that DCVax-L can be prescribed prior to formal approval that might come in 2016. I expect revenues from German sales in […]